Comparison of Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae (COMBAT)

January 12, 2020 updated by: SCARE (Study group for carbapenem resistance)

Comparison of Clinical Outcomes in Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae (COMBAT)

COMBAT trial was contemplated to elucidate unknown clinical relevance of carbapenem heteroresistance among Klebsiella pneumoniae species. Bloodstream infections, type of frequently seen invasive infections that pathogen isolation, identification of antimicrobial resistance mechanisms can be performed efficiently, with carbapenem resistant Klebsiella pneumoniae (CRKp) and carbapenem hetero-resistant Klebsiella pneumoniae will be compared in terms of relevant clinical outcomes such as 30-day mortality rate, 14-day clinical cure rate, 7-day microbiological eradication rate and 90-day relapse/re-infection rate. In addition, underlying molecular resistance mechanisms causing carbapenem hetero-resistance among Klebsiella pneumoniae isolates will be investigated by using whole genome sequences.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Main Objectives:

  1. Conceiving the clinical relevance of carbapenem hetero-resistance phenomenon among Klebsiella pneumoniae strains.
  2. Identification of molecular resistance mechanisms causing carbapenem hetero-resistance among Klebsiella pneumoniae strains
  3. Identification of accuracy of gradient test (e.g. E-test) and disc diffusion test for detection of carbapenem heteroresistance as compared with gold standard PAP analysis

Hypothesis

Main hypothesis

1- 30-day mortality rate is higher in bloodstream infections caused by CRKp than carbapenem hetero-resistant Klebsiella pneumoniae

Secondary hypothesis

  1. 90-day relapse/re-infection rates are similar in CRKp and carbapenem heteroresistant Kp groups. However, carbapenem monotherapy is associated with higher rate of relapse/reinfection rate in treatment of bloodstream infection caused by carbapenem heteoresistant K. pneumonia even if used as high dose and prolonged infusion regimens.
  2. 14-day clinical cure rate is significantly higher in carbapenem heteroresistant Kp group than CRKp group.
  3. 14-day clinical cure rate is significantly lower in patients having BSI caused by carbapenem hetero-resistant K. pneumoniae and treated with carbapenem monotherapy.
  4. 7-day microbiological cure rate is significantly higher in carbapenem heteroresistant Kp group than CRKp group.
  5. 7-day microbiological cure rate is significantly lower in patients having BSI caused by carbapenem heteroresistant K. pneumoniae and treated with carbapenem monotherapy.

Study Design:

Prospective multi-centre multinational study

Setting and study period:

Tertiary care hospitals form different parts of the world will be included in COMBAT trial. Study period is scheduled to be 01.04.2020-01.04.2021 or longer until pre-defined sample size is attained. Local (primary) investigators will collect microbiological and clinical data of participants. Site investigators will screen the microbiology laboratory data in daily interval to identify patients with CRKp or carbapenem hetero-resistant Kp bacteremia. All consecutive patients with monobacterial CRKp or carbapenem hetero-resistant Kp BSI will be eligible to be evaluated for inclusion in the study. Carbapenem resistance will be determined according to 2015 CDC criteria. The presence of carbapenem hetero-resistance among Kp blood culture isolates will be initially determined based on observation of some sub-colonies in inhibition zone of carbapenems. The presence of hetero-resistance against only one type of carbapenems including ertapenem, imipenem, meroepenem will be sufficient to be included. Identification of carbapenem hetero-resistant subpopulations is not infrequent while performing disc diffusion tests or gradient tests (eg. E-test) in our daily practices. However, the exact sensitivity and specificity of these tests for identification of carbapenem hetero-resistance among gram-negative microorganisms are not known yet. The participants with BSI caused by carbapenem hetero-resistant Kp that is defined by disc diffusion or gradient test results will be recruited into carbapenem hetero-resistant Kp group. However, clinical carbapenem hetero-resistant Kp isolates will be transfered to pre-defined reference centres of each country via appropriate transfer culture media. Population analysis profiling (PAP) will be performed for these pathogens in reference centres. Although PAP is recommended method for identification of carbapenem hetero-resistance, it is cumbersome for microbiology laboratories for routine usage. Participants suspected of having BSI with carbapenem hetero-resistant Kp based on routine microbiological methods will be initially included and data of these patients will be recorded but, these patients will be excluded from our final analysis if PAP analysis does not confirm the presence of carbapenem hetero-resistance in these pathogens. PAP analysis will be used as a confirmatory test for identification of carbapenem heteroresistance among Klebsiella pneumoniae isolates. PAP will be performed at the end of patient recruitment and after collection of all isolates in reference centers. Therefore, treatment decisions and any other interventions will not be affected by the results of PAP analysis. PAP will only be used for identification of presence of carbapenem hetero-resistance among suspicious isolates as a gold standard method. This study will be purely observational and no intervention will be in any part of patient follow-up (eg. diagnosis, treatment etc.) and all decisions will be taken by attending physicians. Briefly, PAP analysis will be performed as following: one colony from a culture grown overnight on Columbia agar is inoculated into 5 ml of Luria-Bertani broth. After 24 h of incubation, 0.1 ml of bacterial suspension with a density corresponding 0.5 McFarland is serially diluted and spread onto Mueller-Hinton agar containing two-fold serial dilutions of meropenem, imipenem, ertapenem with concentrations ranging from 0.25 to 256 mg/L. One hundred microliters of ten-fold serial dilution(s) of a 0.5 McFarland suspension is spread on drug-free Mueller-Hinton agar and incubated for 48h at 37 °C to determine the CFUs/ml. Colony counts from three replicate plates are performed for all of the isolates, and mean values are estimated. The number of resistant cells in 0.1 ml of starting bacterial suspension is calculated and the log CFUs/ml is plotted against the antibiotic concentration. The frequency of hetero-resistant subpopulations at the highest drug concentration will be calculated and divided the number of colonies grown on antibiotic-containing plates by the colony counts from the same bacterial inoculum plated onto antibiotic-free plates. A protocol for PAP analysis will be prepared and send to reference centers to perform PAP more smoothly and with same techniques in each reference centers. Site investigators will also collect CRKp isolates and keep these isolates in appropriate conditions until time of transfer for analysis. All CRKp isolates will be sent to the central microbiology laboratories in each country for identification of carbapenemase genes by performing multiplex PCR (polymerized chain reaction).

Sample Size:

To best of our knowledge, there is no study investigating clinical outcomes of bloodstream or other type of invasive infections caused by carbapenem hetero-resistant gram negative bacteria in literature. Therefore, this study will be conducted as a pilot study. Nevertheless, 200 participants for CRKp arm and 100 participants for carbapenem hetero-resistant Klebsiella pneumonaie arm are planned to be involved.

Follow-up:

Participants will be evaluated for microbiological eradication on day 7 by control blood cultures and cultures of primary infection source. If causative pathogen is not eradicated within 7 days follow-up, consecutive cultures will be taken between 7-28 days as being necessary. Patients will also be evaluated for clinical response on day-7 and day-14 by using relevant parameters. All participants will be followed for 90 days after index blood culture date. During this follow-up period, regular assessment starting from blood culture sampling will be carried out and participants will be primarily evaluated for occurrence of any infection (blood stream or other type of invasive infection) in once a month interval if the participants are discharged. Participants will be warned to apply to our centres until the completion of 90-day follow-up period when symptoms of infection develop (eg fever, chills). Also, participants will be informed to call physicians who are primary investigators of particular centre in this study when the participants arrive to hospital clinic or emergency department. Primary investigators will evaluate participants and send their culture samples according to clinical necessity. After review of the results of cultures and clinical presentation, the patients will be allocated into infections with carbapenem resistant or carbapenem hetero-resistant Klebsiella pneumoniae groups. If the participant is discharged before completion of the 90-days, he/she will be contacted in 30 days interval by telephone call to appraise the investigated outcomes.

Microbiological Analysis:

  • Antimicrobial susceptibility tests (AST) will be performed in each center and not be repeated. Therefore, AST results will be obtained from hospital database.
  • PAP (Population analysis profiling) will be performed in reference centers in each country to identify actual hetero-resistant isolates among suspected isolates in which some subpopulations within inhibition zone in gradient test (eg.E-test) or disk diffusion test are identified
  • Multiplex PCR will be used for identification of types of carbapenemase (will be performed in reference centers)
  • Whole genome sequencing will be used to identifiy molecular mechanisms of carbapenem hetero-resistance in clinical isolates (will be performed in reference centers)
  • Colistin resistance will be investigated by broth microdilution method (will be performed in reference centers)
  • EUCAST breakpoints will be used for identification of resistance against all antibiotics except tigecycline in which FDA breakpoints will be applied.
  • The results of antimicrobial susceptiblity and MIC values of carbapenems, colistin, tigecycline, amikacin and gentamycin will be indicated for most resistant subpopulations identified in PAP analysis. MIC values of aforementioned antibiotics will be analyzed in reference centers by using broth microdilution method. For other antibiotics, AST results of parental isolates will be recorded and obtained from hospital database.

Statistical Analysis:

Variables were described using median (interquartile range) or frequency count according to the type of variable. The categorical variables will be compared by Pearson's chi-square or Fisher's exact test if cells have a frequency of 5 or less and continuous variables by Wilcoxon-Mann-Whitney U tests for nonnormally distributed variables or Student's t test for normally distributed variables. The groups (CRKp vs Carbapenem hetero-resisant) were compared by using univariate analysis to define the variables that have significant difference between comparison groups. All univariables with a P value of 0.20 or less will be included in the multivariate Cox regression models by manually selecting them in a backward stepwise manner according to clinical value and their association. VIF (variance inflation factor) will be calculated for each variables incorporated into multivariate model. The best fit model will be picked up according to likelihood ratio test. In another analysis comparing CRKp group and carbapenem hetero-resistant group, a propensity score will be calculated and this score will be incorporated into cox regression analysis model as a confounding parameter. Cox reggression analysis will be applied to compare relevant outcomes such as 30-day mortality and 14-day clinical cure rates.

Survival for 30 days from the first positive blood culture was plotted as Kaplan-Meier curves and the rates of survival were compared by the log rank test to evaluate the effect of carbapenem hetero-resistance. All tests were two-tailed, and significance was set at 0.05 in SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA).

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey, 06100
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All adult (≥18 years) patients who have monobacterial BSI with CRKp or carbapenem hetero-resistant Klebsiella pneumoniae and treated by infectious diseases specialist will be inculded except palliative patients and pregnant or breast-feeding patients. Participants having polimicrobial BSI episode (more than 1 microorganism identified in blood culture) and subsequent BSI episodes caused by CRKp or carbapenem heteroresistant Klebsiella pneumoniae will be excluded.

Description

Inclusion Criteria:

  • All adult (≥18 years) patients who have monobacterial BSI with CRKp or carbapenem hetero-resistant Klebsiella pneumoniae except palliative patients and pregnant or breast-feeding patients

Exclusion Criteria:

  • • <18 years old patients

    • Palliative patients
    • Pregnant or breast-feeding patients
    • Subsequent BSI episodes in the same patients (only first episode will be included)
    • Polimicrobial bacteremia
    • Patients who are not followed and treated by infectious diseases physicians
    • Patients who die within 24 hours after onset of BSI which is defined as the time in which the sample for blood culture is taken.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Carbapenem resistant Klebsiella pneumoniae group
Participants having bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
Drug: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
Other Names:
  • Drug
Carbapenem hetero-resistant Klebsiella pneumoniae group
Participants having bloodstream infection caused by carbapenem-heteroresistant Klebsiella pneumoniae and systemic signs of infection. Only first bloodstream infection episode will be included for each participant
Drug: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
Other Names:
  • Drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
30-day crude mortality
Time Frame: 30-day
Death by any cause
30-day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
14-day clinical response
Time Frame: 14-days

Complete response: Improvement in clinical response resulting in ceasing of antibiotic therapy.

Partial response: Improvement in clinical response with continuation of antibiotic therapy.

No response: No improvement
14-days
90-day relapse or re-infection
Time Frame: 90-days
Relapse/Re-infection: Any type of invasive infections including BSI caused by carbapenem resistant or carbapenem hetero-resistant Kp within 90 days of index BSI
90-days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
7-day microbiological eradication
Time Frame: 7-day
No growth in follow-up culture taken within 7 days of index blood culture
7-day
Resistance genes
Time Frame: 90 days
Whole genome sequences will be used to identify genetic mechanisms (presumably causative genes) of carbapenem hetero-resistance among Klebsiella pneumoniae clinical isolates
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SCARE (Study group for carbapenem resistance)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 1, 2020

Primary Completion (Anticipated)

April 1, 2021

Study Completion (Anticipated)

November 1, 2021

Study Registration Dates

First Submitted

January 4, 2020

First Submitted That Met QC Criteria

January 12, 2020

First Posted (Actual)

January 18, 2020

Study Record Updates

Last Update Posted (Actual)

January 18, 2020

Last Update Submitted That Met QC Criteria

January 12, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • COMBAT121219

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Any data will not be shared with other researchers except the data of participants recruited from their centers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bloodstream Infection

Clinical Trials on Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe